Pathology: metastatic/advanced OC (mOC) - 1st line (L1); mOC - L1 - all population; mOC - L1 - PDL1 positive;
metastatic/advanced OC (mOC) - 1st line (L1) | mOC - L1 - all population | mOC - L1 - PDL1 positive | ||
AGO-OVAR 2.29/ENGOT-ov34, 2024 | IMagyn-050 (all population), 2021 | IMagyn-050 (PDL1 >1%), 2021 | ||
atezolizumab plus SoC | 2 | T1 | T1 | |
atezolizumab plus bevacizumab plus carboplatin plus paclitaxel | 1 | T1 | ||
bevacizumab plus carboplatin and paclitaxel | 0 | T0 | ||
placebo plus SoC | 0 | T0 | T0 |